Correlation Between Caribou Biosciences and Werewolf Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Caribou Biosciences and Werewolf Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Caribou Biosciences and Werewolf Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Caribou Biosciences and Werewolf Therapeutics, you can compare the effects of market volatilities on Caribou Biosciences and Werewolf Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Caribou Biosciences with a short position of Werewolf Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Caribou Biosciences and Werewolf Therapeutics.

Diversification Opportunities for Caribou Biosciences and Werewolf Therapeutics

0.15
  Correlation Coefficient

Average diversification

The 3 months correlation between Caribou and Werewolf is 0.15. Overlapping area represents the amount of risk that can be diversified away by holding Caribou Biosciences and Werewolf Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Werewolf Therapeutics and Caribou Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Caribou Biosciences are associated (or correlated) with Werewolf Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Werewolf Therapeutics has no effect on the direction of Caribou Biosciences i.e., Caribou Biosciences and Werewolf Therapeutics go up and down completely randomly.

Pair Corralation between Caribou Biosciences and Werewolf Therapeutics

Given the investment horizon of 90 days Caribou Biosciences is expected to generate 0.65 times more return on investment than Werewolf Therapeutics. However, Caribou Biosciences is 1.53 times less risky than Werewolf Therapeutics. It trades about -0.02 of its potential returns per unit of risk. Werewolf Therapeutics is currently generating about -0.03 per unit of risk. If you would invest  196.00  in Caribou Biosciences on September 28, 2024 and sell it today you would lose (26.00) from holding Caribou Biosciences or give up 13.27% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Caribou Biosciences  vs.  Werewolf Therapeutics

 Performance 
       Timeline  
Caribou Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Caribou Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's fundamental drivers remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors.
Werewolf Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Werewolf Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Caribou Biosciences and Werewolf Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Caribou Biosciences and Werewolf Therapeutics

The main advantage of trading using opposite Caribou Biosciences and Werewolf Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Caribou Biosciences position performs unexpectedly, Werewolf Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Werewolf Therapeutics will offset losses from the drop in Werewolf Therapeutics' long position.
The idea behind Caribou Biosciences and Werewolf Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.